Results 11 to 20 of about 731,751 (310)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Aksoyalp ZS, Kayki-Mutlu G, Wojnowski L, Michel MC.   +3 more
europepmc   +2 more sources

The contribution of smoking-attributable mortality to differences in mortality and life expectancy among US African-American and white adults, 2000-2019

Demographic Research, 2022
Background: The role of smoking in racial disparities in mortality and life expectancy in the United States has been examined previously, but up-to-date estimates are generally unavailable, even though smoking prevalence has declined in recent decades.
Brian L. Rostron, Cindy M. Chang, Brittny C. Davis Lynn, Chunfeng Ren, Esther Salazar, Bridget K. Ambrose   +5 more
doaj   +1 more source

Adverse Drug Reactions and Toxicity of the Food and Drug Administration–Approved Antisense Oligonucleotide Drugs

Drug Metabolism And Disposition, 2022
The market for large molecule biologic drugs has grown rapidly, including antisense oligonucleotide (ASO) drugs. ASO drugs work as single-stranded synthetic oligonucleotides that reduce production or alter functions of disease-causing proteins through ...
Feryal Alhamadani, Kristy Zhang, Rajvi Parikh, Hangyu Wu, Theodore P Rasmussen, R. Bahal, Xiao-bo Zhong, J. Manautou   +7 more
semanticscholar   +1 more source

Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia

JAMA Network Open, 2022
This systematic review and network meta-analysis compares amitriptyline with Food and Drug Administration–approved treatments for fibromyalgia related to sleep, fatigue, and health-related quality of life outcomes.
H. M. Farag, Ismaeel Yunusa, H. Goswami, I. Sultan, J. Doucette, T. Eguale   +5 more
semanticscholar   +1 more source

Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration–Approved Antisense Oligonucleotide Drugs

Drug Metabolism And Disposition, 2022
Absorption, distribution, metabolism, and excretion (ADME) are the key biologic processes for determination of a drug’s pharmacokinetic parameters, which have direct impacts on efficacy and adverse drug reactions (ADRs).
Julia M. Migliorati, Sunna Liu, Anna Liu, Anagha Gogate, Sreenidhi Nair, Raman Bahal, Theodore P Rasmussen, J. Manautou, Xiao-bo Zhong   +8 more
semanticscholar   +1 more source

Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs

Drug Metabolism And Disposition, 2022
RNA-based oligonucleotide therapeutics are revolutionizing drug development for disease treatment. This class of therapeutics differs from small molecules and protein therapeutics in various ways, including both its mechanism of action and clinical ...
Xing Jing, V. Arya, K. Reynolds, Hobart L Rogers   +3 more
semanticscholar   +1 more source

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action

JAMA Network Open, 2021
Key Points Question How often are anticancer drugs approved based on a new mechanism of action? Findings In this cross-sectional study of 332 US Food and Drug Administration–approved anticancer drugs from 2009 to 2020, 16% of approvals were based on a ...
T. Olivier, A. Haslam, V. Prasad
semanticscholar   +1 more source

Perception of the Food and Drug Administration Electronic Cigarette Flavor Enforcement Policy on Twitter: Observational Study

JMIR Public Health and Surveillance, 2022
Background On January 2, 2020, the US Food and Drug Administration (FDA) released the electronic cigarette (e-cigarette) flavor enforcement policy to prohibit the sale of all flavored cartridge–based e-cigarettes, except for menthol and tobacco flavors ...
Xinyi Lu, Li Sun, Zidian Xie, Dongmei Li
semanticscholar   +1 more source

Food and Drug Administration perspective: Advancing product development for non‐healing chronic wounds

Wound Repair and Regeneration, 2022
The US Food and Drug Administration (FDA) understands that innovative product development is essential to addressing the unmet medical need of non‐healing chronic wounds.
K. Verma, Felisa Lewis, Maryjoy Mejia, Meghana Chalasani, Kendall A Marcus   +4 more
semanticscholar   +1 more source

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?

Clinical pharmacology and therapy, 2021
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity of a chemical agent. They represent a rapidly evolving area of oncology drug development and hold significant promise.
Michael Z. Liao, D. Lu, M. Kågedal, D. Miles, D. Samineni, Stephanie N. Liu, Chunze Li   +6 more
semanticscholar   +1 more source